Lumosa Therapeutics Co's quarterly market cap
increased
from Jun. 2025 (NT$24,679.68 Mil) to Sep. 2025 (NT$48,601.29 Mil) but then
declined
from Sep. 2025 (NT$48,601.29 Mil) to Dec. 2025 (NT$32,765.86 Mil).
Lumosa Therapeutics Co's annual market cap
increased
from Dec. 2023 (NT$11,267.70 Mil) to Dec. 2024 (NT$42,224.25 Mil) but then
declined
from Dec. 2024 (NT$42,224.25 Mil) to Dec. 2025 (NT$32,765.86 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Lumosa Therapeutics Co's Enterprise Value for Today is NT$17,223.07 Mil.
Lumosa Therapeutics Co (ROCO:6535) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6535 vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Lumosa Therapeutics Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lumosa Therapeutics Co Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lumosa Therapeutics Co's Market Cap distribution charts can be found below:
* The bar in red indicates where Lumosa Therapeutics Co's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Lumosa Therapeutics Co's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lumosa Therapeutics Co (ROCO:6535) has a Market Cap of NT$18,004.73 Mil as of Jul. 03, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Lumosa Therapeutics Co and its competitors. According to the industry distribution chart, Lumosa Therapeutics Co ranks #406 out of 1426 companies in the Biotechnology industry, placing it in the top 28.5%.
Is Lumosa Therapeutics Co's Market Cap too high?
Lumosa Therapeutics Co's current Market Cap is NT$18,004.73 Mil. Based on the distribution chart, Lumosa Therapeutics Co ranks #406 out of 1426 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Lumosa Therapeutics Co has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lumosa Therapeutics Co's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lumosa Therapeutics Co ranks #406 out of 1426 companies for Market Cap. This puts Lumosa Therapeutics Co in the upper half of its industry. The industry median Market Cap is 119.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.23, based on 1,426 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Lumosa Therapeutics Co and its competitors. For the Biotechnology industry, the median Market Cap is 119.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lumosa Therapeutics Co's current Market Cap is NT$18,004.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumosa Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, Lumosa Therapeutics Co (ROCO:6535) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$130.90, compared to a current price of NT$107.50 — trading 17.9% below its estimated fair value. The current Market Cap is NT$18,004.73 Mil. Lumosa Therapeutics Co's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Lumosa Therapeutics Co (ROCO:6535), the current Market Cap is NT$18,004.73 Mil as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lumosa Therapeutics Co (ROCO:6535) Overvalued in 2026?
Based on GuruFocus' analysis, Lumosa Therapeutics Co stock appears to be undervalued.
The current stock price of NT$107.50 is trading 17.9% below its estimated GF Value™ of NT$130.90.
GuruFocus considers Lumosa Therapeutics Co to be Modestly Undervalued.
Key valuation signals for ROCO:6535:
Market Cap: NT$18,004.73 Mil
GF Value™: NT$130.90 vs. price of NT$107.50 (17.9% below fair value)
No single metric tells the full story. See the ROCO:6535 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lumosa Therapeutics Co Ltd develops new drugs. The company is engaged in the development of drugs for unmet medical needs in the fields of oncology and Neuroscience. Geographically, it derives a majority of its revenue from Taiwan and also has a presence in Asia, and America. The product pipeline of the company is Neuroscience, which includes LT 1001 for Postoperative Pain, LT 3001 for Acute Ischemic Stroke, LT 5001 for Uremic Pruritus, LT 6001 for Neurological disorder, and Oncology, including LT 2003 for Solid Tumor. It generates revenue from sales of goods.
72GF Score
Get the complete analysis for ROCO:6535
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6535 has been successfully added to your 
